Potassium Dichromate
Active ingredient
Sold as OHM-REN · WHP Sinus Congestion · Snore Stop Extinguisher…
- Drug class
- -
- Availability
- Prescription and OTC
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 3
- FDA reports (12 mo)
- 33
Overview
Plain-language summary, compiled from the cited regulatory records
Potassium Dichromate is an active ingredient used in some pharmaceutical products [1]. Its specific drug class is not detailed in the provided information [1]. This ingredient is indicated for use in sinus conditions [1].
Products containing Potassium Dichromate are available under various brand names, including WHP Sinus Congestion, OHM-REN, and Snore Stop Extinguisher Throat [1]. In the past 12 months, there have been 33 adverse event reports associated with products containing this ingredient [2]. The most frequently reported adverse events include eye pain, nausea, pneumonia, death, and diarrhea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 3 | January 28, 2026 |
USUnited States· FDA
3 products
Uses
**
How to take
DIRECTIONS: Shake 10 times before use. Adults & children above 12 years of age: spray 3 - 4 times under the tongue 2 - 3 times a day or as directed by a health care professional. Children under 12: use half the adult dose.
This is not medical advice. Consult a qualified healthcare professional.
Most-reported reactions to the US regulator (12 mo to June 4, 2026): 33 reports total. [2]
- Eye Pain 5
- Nausea 3
- Pneumonia 3
- Death 2
- Diarrhoea 2
- Dizziness 2
- Epistaxis 2
- Eye Irritation 2
- Fatigue 2
- Foreign Body Sensation In Eyes 2
- Headache 2
- Illness 2
Side effects & warnings
Medicamento Homeopatico. Venta bajo prescripcion medica. Mantengase fuera del alcance de los niños. Mantengase fuera del alcance de los niños.
Medicamento Homeopatico. Venta bajo prescripcion medica. Mantengase fuera del alcance de los niños. Mantengase fuera del alcance de los niños.
This is not medical advice. Consult a qualified healthcare professional.
Sources & citations
- [1]FDA DailyMed · 0ed80100-8bce-4d… · revised January 28, 2026 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.